Autism Spectrum Disorders Clinical Trial
Official title:
Genetic, Biochemical, Behavioral and Neuroimaging Phenotypes of Autism Spectrum Disorders (ASDs)
Verified date | January 2015 |
Source | The Cleveland Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Observational |
The purpose of this research is to better understand the genetic, biochemical, cognitive and behavioral symptom abnormalities that contribute to autism spectrum disorders. The investigators anticipate recruiting at least 100 participants with autism spectrum disorder and large head size, at least 100 participants with autism spectrum disorder without large head size and at least 40 healthy siblings. Biological parents are expected to be recruited only as genetic changes are identified in individuals with autism spectrum disorders to better understand the nature of these genetic changes. Participants are asked to complete cognitive testing, a blood draw, urine collection and measurement of his/her height, weight and head circumference. Parents or caregivers may be asked to complete a diagnostic evaluation and will complete questionnaires that examine the participant's medical and family history as well as his/her current symptoms, functioning, and quality of life. A brief report simply listing and giving a basic description of any behavioral diagnostic information, autism symptoms, adaptive functioning, and a listing of results from cognitive testing will be provided as part of this study.
Status | Completed |
Enrollment | 138 |
Est. completion date | August 2014 |
Est. primary completion date | August 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 2 Years to 50 Years |
Eligibility |
Inclusion Criteria: - Clinical diagnosis of autism - Consent from parents or guardians or an adult with or suspected of having an autism spectrum disorder that does not require a legal guardian or an adult who is the healthy sibling of an individual with an autism spectrum disorder. - Youth ages 2-17 and adults ages 18-50. Youths and adults who are able (some young or severely impaired participants may not be able to provide assent) will be asked to provide assent. - Families with multiple children who meet the above inclusion criteria will be permitted to have as many children participate as they wish. - Youth ages 2-17 and adults ages 18-50 who do not have an autism spectrum disorder or are not suspected of having an autism spectrum disorder and who have a sibling with an autism spectrum disorder who has participated in the present study. Exclusion Criteria: - Clinically significant medical disease that would prohibit participation in the study procedures. - Children younger than 2 years old and adults older than 50 years old. |
Observational Model: Case Control, Time Perspective: Cross-Sectional
Country | Name | City | State |
---|---|---|---|
United States | Cleveland Clinic Center for Autism | Cleveland | Ohio |
Lead Sponsor | Collaborator |
---|---|
The Cleveland Clinic | National Center for Research Resources (NCRR), National Institutes of Health (NIH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total Brain Volume | Baseline | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02625116 -
ELENA Cohort: A Long-term Longitudinal Study in a Pediatric Sample With Autism Spectrum Disorders
|
||
Not yet recruiting |
NCT06381856 -
Improving Participation of Autistic Children and Adolescents in the Habilitation Process
|
||
Recruiting |
NCT02280746 -
Gluten for Autism Spectrum Disorders
|
N/A | |
Completed |
NCT01945957 -
Brain Imaging of Intranasal Oxytocin Treatment in Autism
|
Phase 1 | |
Completed |
NCT01661855 -
A Pilot Study of Riluzole Versus Placebo in the Treatment of Children and Adolescents With ASD
|
Phase 2 | |
Completed |
NCT01691066 -
Pivotal Response Treatment for Infants At-Risk for Autism Spectrum Disorder
|
N/A | |
Completed |
NCT01592747 -
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
|
Phase 2 | |
Completed |
NCT01780090 -
Handheld Technology for Speech Development in Students With Autism
|
N/A | |
Completed |
NCT01694667 -
Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder
|
Phase 2 | |
Active, not recruiting |
NCT01417026 -
Intranasal Oxytocin and Learning in Autism
|
Phase 2 | |
Enrolling by invitation |
NCT01364818 -
Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment
|
N/A | |
Completed |
NCT01695200 -
Omega-3 Fatty Acids in Autism Spectrum Disorders
|
Phase 4 | |
Completed |
NCT02300597 -
Internet-based Support for Young People With ADHD and Autism - a Controlled Study
|
N/A | |
Not yet recruiting |
NCT00695812 -
The Development of Younger Siblings of Children With Autism Now at 10 Years of Age
|
N/A | |
Completed |
NCT01675414 -
Understanding Gastrointestinal Conditions in Children With Autism Spectrum Disorder (ASD)
|
N/A | |
Recruiting |
NCT05910502 -
Project AFECT (Autism Family Empowerment Coaching and Training Program)
|
N/A | |
Completed |
NCT02081027 -
Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders
|
Early Phase 1 | |
Completed |
NCT02797379 -
The Development of a Psychoeducational Tool to Manage Anxiety in People With Autism Spectrum Disorders
|
N/A | |
Terminated |
NCT01730079 -
Near Infrared Spectroscopy in Children With Autism and ADHD
|
||
Completed |
NCT01603225 -
Transcranial Direct Current Stimulation and Autism
|